Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Netherlands-based biomedical research company InteRNA Technologies and Cenix BioScience, a contract research organization, have signed a research agreement comprising functional screens in human cell lines using InteRNA's proprietary library of miRNAs.
Subscribe to our email newsletter
Cenix will apply InteRNA’s lentiviral-based miRNA overexpression library in high throughput screening assays in combination with high content, multi-parametric phenotypic analyses to identify the biological role of individual miRNAs and novel therapeutic targets in the area of cancer.
Roel Schaapveld, COO of InteRNA Technologies, said: “We are very much pleased to work in collaboration with Cenix to further advance our drug discovery efforts to identify miRNA regulated targets for cancer therapy. Cenix’s unique expertise on small RNA-based high-throughput screening and phenotypic analyses will be instrumental in our discovery programs.”